Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

GNMX

Corgi Genomics & Precision Medicine ETF (GNMX)

Rating:60Neutral
Price Target:$37.00▲(5.88% Upside)

GNMX, the Corgi Genomics & Precision Medicine ETF, is supported by several high-quality holdings like Incyte, Vertex Pharmaceuticals, Genmab, Thermo Fisher, and Illumina, which show strong financial performance, solid growth prospects, and generally positive long-term outlooks. However, weaker holdings such as Iovance Biotherapeutics and Revolution Medicines, which face ongoing losses, cash flow issues, and bearish trends, weigh on the fund’s overall quality. The main risk factor is the ETF’s focus on genomics and biotech, a sector where many companies have volatile earnings, high valuations, and significant uncertainty around future profitability.

Positive Factors
Strong Recent PerformanceThe ETF has delivered strong gains so far this year and in recent months, showing solid momentum in its niche area.
Leading Health Care InnovatorsTop holdings like Thermo Fisher, Moderna, and Vertex Pharmaceuticals have shown strong or steady performance, helping drive the fund’s returns.
Focused Exposure to Genomics and Precision MedicineA high allocation to health care and genomics-related companies gives investors targeted exposure to a growing medical innovation theme.
Negative Factors
High Sector ConcentrationWith most assets in health care, the ETF is heavily exposed to swings in one industry rather than being broadly diversified.
Small Fund SizeThe relatively low assets under management may lead to higher trading costs or a greater risk the fund could be closed if it does not grow.
Single-Country FocusBecause the ETF is almost entirely invested in U.S. companies, investors get limited diversification across different global markets.

GNMX vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%60%SPY+14.55%GNMX+35.94%Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
1.24M
Region
Global
Expense Ratio
0.35%
Beta
0.58
Issuer
Corgi
Inception Date
May 06, 2026
Dividend Yield
N/A
Asset Class
Equity
Index Tracked
No Underlying Index

GNMX Summary

The Corgi Genomics & Precision Medicine ETF (GNMX) is a healthcare-focused fund that invests in companies using DNA and data to develop new tests and treatments. It follows a genomics and precision medicine theme rather than a broad market index, holding firms involved in gene editing, cancer therapies, and advanced diagnostics. Well-known names in the fund include Thermo Fisher and Moderna. Someone might invest in GNMX for long-term growth and to tap into cutting-edge medical innovation. However, because it is heavily focused on genomics and biotech, its price can be very volatile and may swing more than the overall market.

How much will it cost me?

This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s higher than the cost of a typical broad, passively managed index ETF because this is a specialized, actively managed fund focused on genomics and precision medicine companies.

What would affect this ETF?

This genomics and precision medicine ETF could benefit if new DNA-based tests and targeted treatments from companies like Thermo Fisher, Vertex, and Moderna gain wider medical acceptance, if healthcare systems increase spending on advanced diagnostics, and if supportive drug-approval policies encourage innovation globally. On the other hand, it could be hurt by tighter drug pricing rules, clinical trial setbacks at smaller biotech holdings, shifts in healthcare budgets away from high-cost therapies, or market pullbacks that hit high-growth health care stocks especially hard.

GNMX Top 10 Holdings

GNMX is leaning heavily into cutting-edge biotech, with Moderna and Iovance acting as key engines of recent gains as their pipelines and momentum stay firmly in the “rising” camp. Illumina and Thermo Fisher provide a steadier backbone, benefiting from demand for sequencing tools and lab equipment. On the weaker side, Guardant Health and 10x Genomics have been more mixed, occasionally dragging on performance as investors wrestle with their profitability and growth narratives. The fund is overwhelmingly health care–focused and globally diversified, but thematically concentrated in genomics and precision medicine.

GNMX top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
MRNAMRNAModerna11.28%$144.49K$93.61B794.91%59Neutral
TMOTMOThermo Fisher9.42%$120.58K$259.15B20.70%72Outperform
VRTXVRTXVertex Pharmaceuticals6.28%$80.41K$137.57B23.95%78Outperform
GMABGMABGenmab4.48%$57.32K$31.11B69.87%76Outperform
ILMNILMNIllumina3.84%$49.19K$31.68B72.61%71Outperform
GHGHGuardant Health3.30%$42.25K$20.95B61.16%61Neutral
RVMDRVMDRevolution Medicines3.06%$39.21K$38.14B167.61%52Neutral
INCYINCYIncyte2.81%$35.95K$24.81B14.76%81Outperform
TXGTXG10x Genomics2.75%$35.18K$7.77B255.90%60Neutral

GNMX Technical Analysis

Technical Analysis SentimentNegative
Last Price34.94

Price Trends

50DMA36.76Negative
100DMA34.42Positive

Market Momentum

MACD-0.25Positive
RSI42.11Neutral
STOCH14.42Positive

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNMX, the sentiment is Negative. The current price of 34.94 is below the 20-day moving average (MA) of 37.11, below the 50-day MA of 36.76, and compared to the 200-day MA of , indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 42.11 is Neutral, neither overbought nor oversold. The STOCH value of 14.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNMX.

GNMX Peer Comparison

Comparison Results

GNMX against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
GNMXGNMX$34.94$37.00(5.88% Upside)$1.24M0.35%60Neutral
FFNDFFND$31.35$37.99(21.19% Upside)$94.32M0.98%65Neutral
FDCFFDCF$50.33$64.33(27.84% Upside)$81.09M0.50%70Neutral
IQMIQM$87.79$134.44(53.14% Upside)$72.24M0.50%69Neutral
HECOHECO$48.23$87.27(80.96% Upside)$62.91M0.90%64Neutral
HELXHELX$42.51$54.50(28.20% Upside)$34.34M0.50%62Neutral

Performance Comparison

0%20%40%60%GNMXFFNDFDCFIQMHECOHELXJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GNMX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GNMXCorgi Genomics & Precision Medicine ETF34.949.2435.94%
FFNDFuture Fund Active ETF31.352.057.01%
FDCFFidelity Disruptive Communications ETF50.334.249.19%
IQMFranklin Intelligent Machines ETF87.792.893.40%
HECOSPDR Galaxy Hedged Digital Asset Ecosystem ETF48.237.8819.54%
HELXFranklin Genomic Advancements ETF42.517.6621.98%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.